Capricor Therapeutics (CAPR) Misses Q2 EPS by 9c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Boeing wins $2 billion satellite contract from DoW
• Pacific Booker Minerals Inc. Adopts Advance Notice Policy for Director Elections